Understanding and managing the possible adverse effects associated with bevacizumab

American Journal of Health-System Pharmacy

Volumn 66, Issue 11, 2009, Pages 999-1013

  Shord, Stacy S ^a   Bressler, Linda R ^a   Tierney, Lauryn A ^a   Cuellar, Sandra ^a   George, Amina ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antibodies; Bevacizumab; Hypertension; Toxicity

Indexed keywords

ALPHA INTERFERON; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CALCIUM CHANNEL BLOCKING AGENT; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HYDRALAZINE; IRINOTECAN; LOW MOLECULAR WEIGHT HEPARIN; MINOXIDIL; OXALIPLATIN; PACLITAXEL; THIAZIDE DIURETIC AGENT; WARFARIN;

ADVERSE OUTCOME; ARTERY THROMBOSIS; BLEEDING; BLOOD PRESSURE; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG WITHDRAWAL; HEALTH CARE MANAGEMENT; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; INTESTINE PERFORATION; LEUKOENCEPHALOPATHY; NOSE SEPTUM PERFORATION; PATHOPHYSIOLOGY; PATIENT MONITORING; PATIENT SAFETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; RASH; REVIEW; RISK FACTOR; RISK REDUCTION; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT;

EID: 66949140795     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080455     Document Type: Review

References (106)

1. Jiang BH, Liu LZ. AKT signaling in regulating angiogenesis. Curr Cancer Drug Targets. 2008; 8:19-26. (Pubitemid 351237906)
2. Ho QT, Kuo CJ. Vascular endothelial growth factor: biology and therapeutic applications. Int J Biochem Cell Biol. 2007; 39:1349-1357 (Pubitemid 47031045)
3. Ignoffo RJ. Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor. Am J Health-Syst Pharm. 2004; 61(21, suppl 5):S21-6.
4. Zondor SD, Medina PJ. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother. 2004; 38:1258-1264 (Pubitemid 38802172)
5. Avastin (bevacizumab) package insert. San Francisco: Genentech, Inc.; 2008.
6. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42: 1206-1252 (Pubitemid 37553153)
7. Kiefer FN, Neysari S, Humar R et al. Hypertension and angiogenesis. Curr Pharm Des. 2003; 9:1733-1744 (Pubitemid 36966033)
8. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007; 96:1788-1795 (Pubitemid 46912024)
9. Hood JD, Meininger CJ, Ziche M et al. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol. 1998; 274(3, pt. 2):H1054-8. (Pubitemid 128734103)
10. Horowitz JR, Rivard A, van der Zee R et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol. 1997; 17:2793-2800 (Pubitemid 28016023)
11. Nixon A, Allen J, Miller E et al. Clinical evaluation of nitric oxide responses to anti-VEGF therapy with bevacizumab. J Clin Oncol. 2007; 25(suppl):14039. Abstract.
12. Mourad JJ, des Guetz G, Debbabi H et al. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol. 2008; 19:927-934
13. Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis. 2004; 7:193-201.
14. Veronese ML, Mosenkis A, Flaherty KT et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol. 2006; 24:1363-1369 (Pubitemid 46621999)
15. Starling N, Cunningham D. Complications of vascular endothelial growth factor inhibitors in colorectal cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Principles and practice of oncology. Philadelphia: Lippincott, Williams and Wilkins; 2005:1-15.
16. Zhu X, Wu S, Dahut WL et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007; 49:186-193 (Pubitemid 46178407)
17. Chen HX, Mooney M, Boron M et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol. 2006; 24:3354-3360 (Pubitemid 46638889)
18. Cohen MH, Gootenberg J, Keegan P et al. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist. 2007; 12:356-361 (Pubitemid 46556802)
19. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007; 25:1539-1544 (Pubitemid 46733080)
20. Giantonio BJ, Levy DE, O'Dwyer PJ et al. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group Study E2200. Ann Oncol. 2006; 17:1399-1403 (Pubitemid 44400378)
21. Hurwitz HI, Fehrenbacher L, Hainsworth JD et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005; 23:3502-3508
22. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355:2542-2550 (Pubitemid 44917502)
23. Fehrenbacher L, O'Neill V, Belani C et al. A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. J Clin Oncol. 2006; 24(suppl):379S. Abstract.
24. Herbst RS, Johnson DH, Mininberg E et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005; 23:2544-2555
25. Ramaswamy B, Elias AD, Kelbick NT et al. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res. 2006; 12:3124-3129 (Pubitemid 43837360)
26. Zhu AX, Blaszkowsky LS, Ryan DP et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006; 24:1898-1903 (Pubitemid 46638989)
27. Shah MA, Ramanathan RK, Ilson DH et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006; 24:5201-5206 (Pubitemid 46631363)
28. Monk BJ, Han E, Josephs-Cowan CA et al. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol. 2006; 102:140-144 (Pubitemid 44056265)
29. Kindler HL, Friberg G, Singh DA et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005; 23:8033-8040 (Pubitemid 46657405)
30. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003; 349:427-434 (Pubitemid 36910021)
31. D'Adamo DR, Anderson SE, Albritton K et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol. 2005; 23:7135-7142 (Pubitemid 46260301)
32. Burt VL, Whelton P, Roccella EJ et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995; 25:305-313
33. Raman A, Lombardo J, Chandrasekhar R et al. Bevacizumab (BV) related adverse events among various age groups of elderly patients with advanced colorectal cancer. J Clin Oncol. 2007; 25(suppl):14546. Abstract.
34. Centers for Drug Evaluation and Research. Approval package for application number STN-125085/0; 2008. www.fda.gov/cder/foi/nda/2004/STN-125085- Avastin-medr-P1.pdf (accessed 2008 Jul 25).
35. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003; 21:60-65
36. Kabbinavar FF, Schulz J, McCleod M et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005; 23:3697-3705 (Pubitemid 46252464)
37. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004; 22:2184-2191 (Pubitemid 41095154)
38. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350:2335-2342 (Pubitemid 38702844)
39. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005; 23:792-799 (Pubitemid 46224178)
40. Yau T, Chan P, Chu K et al. Bevacizumab-based chemotherapy in Hong Kong Chinese patients with metastatic colorectal cancer. www.asco.org/ASCO/ Abstracts+%26+Virtual+Meeting/Abstracts?vmview=abst-detail-view& confID=45&abstractID=10244 (accessed 2009 Mar 5).
41. Cobleigh MA, Langmuir VK, Sledge GW et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol. 2003; 30(5, suppl 16):117-124 (Pubitemid 37433402)
42. Lowery M, Power D, Behbehani A et al. Hypertension is a significant adverse effect of bevacizumab treatment. J Clin Oncol. 2007; 25(suppl):14134. Abstract.
43. Motl S. Bevacizumab in combination chemotherapy for colorectal and other cancers. Am J Health-Syst Pharm. 2005; 62:1021-1032 (Pubitemid 40676638)
44. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology. 2005; 69(suppl 3):25-33. (Pubitemid 41680950)
45. Pande AU, Lombardo JC, Fakih MG. Bevacizumab induced hypertension: a manageable toxicity. J Clin Oncol. 2006; 24(suppl):619S. Abstract.
46. Rosiak J, Sadowski L. Hypertension associated with bevacizumab. Clin J Oncol Nurs. 2005; 9:407-411
47. Siddiqui AJ, Mansson-Broberg A, Gustafsson T et al. Antagonism of the renin-angiotensin system can counteract cardiac angiogenic vascular endothelial growth factor gene therapy and myocardial angiogenesis in the normal heart. Am J Hypertens. 2005; 18:1347-1352 (Pubitemid 41400206)
48. BC Cancer Agency. Management guidelines for bevacizumab-related side effects in patients with colorectal cancer. www.bccancer.be.ca/NR/rdonlyres/ 6058B58E-E540-4C29-94C0-3E1A94FD1571/19258/Managementforbevacizumabsideeffects- 1Dec06.pdf (accessed 2008 Jul 21).
49. Pesce AJ, First MR. Proteinuria: an integrated review. Chap. 4. New York: Dekker; 1979:80-96.
50. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008; 358:1129-1136
51. Sugimoto H, Hamano Y, Charytan D et al. Neutralization of circulating vascular endothelial growth factor (VEGF-A) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem. 2003; 278:12605-12608 (Pubitemid 36800018)
52. George BA, Zhou XJ, Toto R. Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis. 2007; 49:e23-9. (Pubitemid 46164815)
53. Hurwitz H, Kabbinavar F. Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer. Oncology. 2005; 69(suppl 3):17-24. (Pubitemid 41680949)
54. Genentech. Important drug warning, subject: microangiopathic hemolytic anemia (MAHA) in patients treated with Avastin (bevacizumab) and sunitinib malate. www.gene.com/gene/products/information/pdf/avastin-maha-letter.pdf (accessed 2008 Jul 21).
55. Feldman DR, Ginsberg MB, Flombaum C et al. Phase I trial of bevacizumab plus sutinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008; 26(suppl): abstract 5100.
56. Advani A, Kelly DJ, Advani SL et al. Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proc Natl Acad Sci. 2007; 104:14448-14453 (Pubitemid 350003281)
57. Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol. 2006; 33(5, suppl 10):S26-34. (Pubitemid 44634007)
58. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. www.kidney.org/Professionals/Kdoqi/guidelines-ckd/toc.htm (accessed 2008 Jul 25).
59. Martel CL, Ebrahimi B, Horns RC et al. Incidence of bevacizumab (BE) related toxicities: association of hypertension (HTN) and proteinuria (PTN), a BE toxicity syndrome (BETS). J Clin Oncol. 2005; 23(suppl):8062. Abstract.
60. Dincer M, Altundag K. Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension. Ann Pharmacother. 2006; 40:2278-2279 (Pubitemid 44954457)
61. Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol. 2003; 21:3542.
62. Came GJ, Stonelake PS, Lip GY et al. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia. 2002; 4:465-473 (Pubitemid 35417069)
63. Zwicker JI, Furie BC, Furie B. Cancer-associated thrombosis. Crit Rev Oncol Hematol. 2007; 62:126-136
64. Donadon M, Vauthey JN, Loyer EM et al. Portal thrombosis and steatosis after preoperative chemotherapy with FOLFIRI-bevacizumab for colorectal liver metastases. World J Gastroenterol. 2006; 12:6556-6558 (Pubitemid 44742595)
65. Shah MA, Ilson D, Kelsen DP. Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizurnab-based therapy. J Clin Oncol. 2005; 23:2574-6. (Pubitemid 47053842)
66. Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003; 107(23, suppl 1):I9-16. (Pubitemid 41289266)
67. Billett HH. Antiplatelet agents and arterial thrombosis. Cardiol Clin. 2008; 26: vi,189-201.
68. Skillings J, Johnson D, Miller K. Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy. J Clin Oncol. 2005; 23(suppl):3019. Abstract.
69. Buller HR, Agnelli G, Hull RD et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(3, suppl):401S-428S. (Pubitemid 39297960)
70. Grogan KM, Wong C, Nutescu EA et al. Examining differences in weekly warfarin dose in patients with and without cancer. Ther Drug Monit. 2007; 29:638-643 (Pubitemid 47494064)
71. Hambleton J, Novotny WF, Hurwitz H et al. Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation. J Clin Oncol. 2004; 22(suppl):3528. Abstract.
72. Papetti M, Herman IM. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol. 2002; 282:C947-70. (Pubitemid 34663101)
73. Kang T, Jin T, Peereboom D. Irinotecan and bevacizumab in progressive primary brain tumors: the Cleveland Clinic experience. J Clin Oncol. 2007; 25(suppl):2077. Abstract.
74. August DA, Serrano D, Poplin E. "Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy. J Surg Oncol. 2008; 97:180-185 (Pubitemid 351169051)
75. Reddy SK, Morse MA, Hurwitz HI et al. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg. 2008; 206:96-106. (Pubitemid 350267242)
76. Lyons JA, Silverman P, Remick SC et al. Toxicity results and early outcome data on a randomized phase II study of docetaxel ± bevacizumab for locally advanced, unresectable breast cancer. J Clin Oncol. 2006; 24(suppl):3049. Abstract.
77. Ellis LM, Curley SA, Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol. 2005; 23:4853-4855 (Pubitemid 46223989)
78. Berry S, Michael M, Kretzschmar A et al. Lack of effect of starting bevacizumab shortly after venous access device implantation on wound healing/bleeding complications: preliminary results from first BEAT. Proceedings of the Gastrointestinal Cancer Symposium. San Francisco, CA; 2006.
79. Stinchcombe TE, Socinski MA. Considerations for second-line therapy of non-small cell lung cancer. Oncologist. 2008; 13(suppl 1):28-36.
80. Badgwell BD, Camp ER, Feig B et al. Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol. 2008; 19:577-582 (Pubitemid 351325682)
81. Han ES, Monk BJ. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol. 2007; 105:3-6. (Pubitemid 46441477)
82. Heinzerling JH, Huerta S. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management. Curr Surg. 2006; 63:334-337 (Pubitemid 44340939)
83. Saif MW, Mehra R. Incidence and management of bevacizumab-related toxicities in colorectal cancer. Expert Opin Drug Saf. 2006; 5:553-566 (Pubitemid 44468452)
84. Traina TA, Norton L, Drucker K et al. Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer. Oncologist. 2006; 11:1070-1071 (Pubitemid 44788397)
85. Fakih MG, Lombardo JC. Bevacizumab-induced nasal septum perforation. Oncologist. 2006; 11:85-86
86. Hinchey J, Chaves C, Appignani B et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996; 334:494-500. (Pubitemid 26067737)
87. Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med. 2006; 354:980-982 Letter. (Pubitemid 43313687)
88. Allen JA, Adlakha A, Bergethon PR. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFTRI regimen for metastatic colon cancer. Arch Neurol. 2006; 63:1475-1478 (Pubitemid 44547561)
89. Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med. 2006; 354:980-982 Letter. (Pubitemid 43313688)
90. Saif MW, Longo WL, Israel G. Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer. Clin Colorectal Cancer. 2008; 7:144-148
91. Gotlib V, Khaled S, Lapko I et al. Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anticancer Drugs. 2006; 17:1227-1229 (Pubitemid 44673405)
92. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007; 12:601-609 (Pubitemid 350012124)
93. Schwartzberg LS, Stepanski EJ, Fortner BV et al. Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences. Support Care Cancer. 2008; 16:393-398 (Pubitemid 351667051)
94. Reidy D, Chung K, Timoney J et al. Bevacizumab 5mg/kg can be safely infused over 10 minutes. J Clin Oncol. 2007; 25(suppl):4135. Abstract.
95. Viale PH, Fung A, Zitella L. Advanced colorectal cancer: current treatment and nursing management with economic considerations. Clin J Oncol Nurs. 2005; 9:541-552
96. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008; 26:2013-9. [Errata, J Clin Oncol. 2008; 26:3110; J Clin Oncol. 2009; 27:653.]
97. Tol J, Koopman M, Rodenburg CJ et al. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIR02 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol. 2008; 19:734-738
98. Jackman DM, Kindler HL, Yeap BY et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 2008; 113:808-814
99. Lilenbaum R, Raez L, Tseng J et al. Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced non-small cell lung cancer. J Thorac Oncol. 2008; 3:511-515 (Pubitemid 351630279)
100. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007; 357:2666-2676
101. Di Lorenzo G, Figg WD, Fossa SD et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol. 2008; 54:1089-1094
102. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007; 370:2103-2111 (Pubitemid 350296300)
103. Ko AH, Dito E, Schillinger B et al. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs. 2008; 26:463-471
104. Nimeiri HS, Oza AM, Morgan RJ et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2008; 110:49-55.
105. Siegel AB, Cohen EI, Ocean A et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008; 26:2992-2998
106. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007; 25: 4722-4729